Korea Takes Its First Step Reimbursing IO Drugs
Amid repeated calls industry, South Korea decides to pay for Keytruda and Opdivo in its first reimbursement of immuno-oncology drugs, albeit at limited scope. The government is poised to expand reimbursement of IO drugs going forward amid its plan to significantly expand health insurance coverage.
You may also be interested in...
Despite the regime change, South Korea remained generally supportive of the pharma and biotech industry in 2017. With comprehensive long-term plans proposed to nurture these sectors, the government appears poised to pursue its favorable stance towards industry in the coming year.
Korea's National Health Insurance Service and AstraZeneca reach an agreement on reimbursement of Tagrisso, sharply reducing financial burdens of NSCLC patients in the country. Tough price negotiations between the two sides underlines the difficulties pricey innovative drugs face to get reimbursed in the country.
In its first announcement of major health care measures since the Moon Jae-in administration took charge, South Korea unveils steps to hike its national health insurance coverage ratio to levels in advanced countries, raising concerns that this might lead to sharp drug price cuts.